Boehringer Ingelheim confirms BioWhittaker agreement:
This article was originally published in Clinica
Boehringer Ingelheim has confirmed it will buy BioWhittaker's interest in the companies' joint venture for cell culture products in Verviers, Belgium (see Clinica No 653, p 13). Under the recently signed agreement, Boehringer Ingelheim says it intends to integrate the joint venture into its affiliated distributors in Spain, Austria and Germany. However, until the restructuring takes place, BioWhittaker will maintain its exclusive distribution arrangements in those countries. BioWhittaker has also agreed to sell to the joint venture its distribution subsidiary in France. Its UK subsidiary will continue to be the joint venture's exclusive distributor in the UK and Ireland. BioWhittaker has the option to repurchase its interest in the venture for an agreed price over a designated period.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.